Form 4: Allovir Director Morana Jovan-Embiricos Receives 35,000 Restricted Stock Units

Director Morana Jovan-Embiricos of Allovir, Inc. reports the acquisition of 35,000 restricted stock units (RSUs) and indirect beneficial ownership of millions of shares through various entities.

Summary

• Morana Jovan-Embiricos, a director of Allovir, Inc., filed a Form 4 disclosing changes in beneficial ownership.
• On June 6, 2024, Jovan-Embiricos acquired 35,000 restricted stock units (RSUs) under the company's 2020 Stock Option and Grant Plan.
• These RSUs will vest on the earlier of June 6, 2025, or the next annual meeting of Allovir's stockholders, contingent upon continued service on the Board of Directors.
• Jovan-Embiricos also reported indirect beneficial ownership of shares held by several entities, including F2 TPO Investments, LLC (668,072 shares), F2 MG Ltd. (2,059,884 shares), F2 MC, LLC (2,038,583 shares), F2 Capital I 2020 LLC (4,193,874 shares), F2 Bioscience AV 2022 LLC (867,678 shares), and ElevateBio LLC (16,674,766 shares).
• Jovan-Embiricos disclaims beneficial ownership of these indirectly held shares except to the extent of her pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Positives

• The grant of RSUs to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service on the board.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The acquisition of RSUs by a director can align their interests with shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates